EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib

Cass G G Sunga iD, Michael S Higgins, Robert W Ricciotti, Yajuan J Liu, Lee D Cranmer iD

Cancer Reports · 2023-03 · 6 (3)

DOI: 10.1002/cnr2.1792 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, online erschienen am 08.02.2023. Verfasst von Cass G G Sunga und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Piperidines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammatory myofibroblastic tumor (IMT) is an ultra‐rare soft tissue neoplasm associated with fusion proteins encompassing the anaplastic lymphoma kinase (ALK) protein fused to a variety of partner proteins. Data regarding response to ALK‐targeting agents based on fusion partner is limited. Case A 30‐year‐old female sought emergency care after onset of abdominal and lower back pain in 2019. Computed tomography (CT) demonstrated a cystic, mesenteric mass within the pelvis measuring up to 8.9 cm. Complete laparoscopic excision of the mass from the mesentery of the right colon and terminal ileum was performed. Pathologic assessment revealed IMT with a fusion between sequestosome 1 and ALK ( SQSTM1::ALK ), described in only two other cases of IMT. Four months after surgery, CT revealed multi‐focal, unresectable disease recurrence. She was referred to the University of Washington/Fred Hutchinson Cancer Center and placed on therapy with alectinib, after which she experienced a partial response. Three years after IMT recurrence, disease remains under control.

Conclusion

This is the third reported case of IMT associated with the novel SQSTM1::ALK fusion protein, and the second treated with alectinib. Treatment with the ALK inhibitor alectinib appears to be active in this setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalPiperidinesFemaleHumansAdultAnaplastic Lymphoma KinaseSequestosome-1 ProteinCarbazoles

Stichwörter der Autor:innen

alectinibanaplastic lymphoma kinaseinflammatory myofibroblastic tumorsequestosome 1

Substanzen

Anaplastic Lymphoma KinaseSequestosome-1 ProteinPiperidinesalectinibCarbazolesSQSTM1 protein, human

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
  • PeaceHealth Department of General and Colorectal Surgery, Bellingham, Washington, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, USA.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

ORCID-Profile: Cass G G Sunga, Lee D Cranmer

Zitieren

APA

Sunga, C. G. G., Higgins, M. S., Ricciotti, R. W., Liu, Y. J., & Cranmer, L. D. (2023). Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib. Cancer Reports, 6(3). https://doi.org/10.1002/cnr2.1792

Vancouver

Sunga CGG, Higgins MS, Ricciotti RW, Liu YJ, Cranmer LD. Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib. Cancer Reports. 2023;6(3). doi:10.1002/cnr2.1792

BibTeX
@article{Sunga2023,
  author = {Sunga, Cass G G and Higgins, Michael S and Ricciotti, Robert W and Liu, Yajuan J and Cranmer, Lee D},
  title = {Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib},
  journal = {Cancer Reports},
  year = {2023},
  volume = {6},
  number = {3},
  doi = {10.1002/cnr2.1792}
}
Kostenlos starten →